Bui V

References (3)

Title : Daraxonrasib (RMC-6236) pharmacokinetics: impact of transporters and drug-metabolizing enzymes on a first-in-class pan-RAS molecular glue - Schinkel_2026_Pharmacol.Res__108226
Author(s) : Schinkel A , Arguedas D , Bui V , Law T , Rijmers J , Tissier R , Beijnen JH , van Tellingen O , Lebre MC
Ref : Pharmacol Res , :108226 , 2026
Abstract :
PubMedSearch : Schinkel_2026_Pharmacol.Res__108226
PubMedID: 42107507

Title : Brain Exposure to the Macrocyclic ALK Inhibitor Zotizalkib is Restricted by ABCB1, and Its Plasma Disposition is Affected by Mouse Carboxylesterase 1c - Rijmers_2024_Mol.Pharm__
Author(s) : Rijmers J , Sparidans RW , Acda M , Loos NHC , Epeslidou E , Bui V , Lebre MC , Tibben M , Beijnen JH , Schinkel AH
Ref : Mol Pharm , : , 2024
Abstract :
PubMedSearch : Rijmers_2024_Mol.Pharm__
PubMedID: 39312722

Title : ABCB1 attenuates brain exposure to the KRAS(G12C) inhibitor opnurasib whereas binding to mouse carboxylesterase 1c influences its plasma exposure - Rijmers_2024_Biomed.Pharmacother_175_116720
Author(s) : Rijmers J , Retmana IA , Bui V , Arguedas D , Lebre MC , Sparidans RW , Beijnen JH , Schinkel AH
Ref : Biomed Pharmacother , 175 :116720 , 2024
Abstract :
PubMedSearch : Rijmers_2024_Biomed.Pharmacother_175_116720
PubMedID: 38733773